Tempus has partnered with Ambry Genetics® to provide germline testing. These tests are designed to specifically detect various germline variants associated with hereditary cancer syndromes.

1. **xG (CancerNext®)**
   36 gene panel associated with common hereditary cancer types analyzed by DNA sequencing.

2. **xG+ (CancerNext-Expanded®)**
   77 gene panel associated with both common and rare hereditary cancer types analyzed by DNA sequencing.

**ORDERING OPTIONS**

- xG (CancerNext®) / xG+ (CancerNext-Expanded®) can be ordered as a standalone test or as a confirmatory test for potential germline findings from Tempus xT tumor + normal match sequencing, helping to possibly identify more patients at risk of hereditary cancer.

- Familial variant testing available for at-risk family members at no additional cost if ordered within 90 days of original xG (CancerNext®) / xG+ (CancerNext-Expanded®) report.

- Through one platform, somatic and germline testing can be ordered.

- Flexible ordering options via online ordering through Tempus Hub or paper requisition.

**REPORTING**

- Reports include pathogenic and likely pathogenic variants as well as variants of uncertain significance. Amended reports are provided for variant reclassifications when available.

- Clinician management resources and patient guides are provided with reports when available.

- Results expected to be available approximately **14-21 days** after specimen receipt.

- Reports delivered through Tempus Hub or email/fax.

**SPECIMEN AND KIT REQUIREMENTS**

- xG (CancerNext®) / xG+ (CancerNext-Expanded®) blood collection kit: 4ml lavender top EDTA tube.

- xG (CancerNext®) / xG+ (CancerNext-Expanded®) saliva collection kit: 1 Oragene (OGD-510) self-collection container.

- Cultured fibroblast specimens require completion of the additional Test Requisition for Tissue Culturing form.

Samples will be sent to Ambry Genetics® using the dedicated Ambry collection kits.
## Gene Lists

**xG+ (CancerNext-Expanded®) — 77 Genes:**

<table>
<thead>
<tr>
<th>Gene</th>
</tr>
</thead>
<tbody>
<tr>
<td>AIP</td>
</tr>
<tr>
<td>ALK</td>
</tr>
<tr>
<td>APC</td>
</tr>
<tr>
<td>ATM</td>
</tr>
<tr>
<td>AXIN2</td>
</tr>
<tr>
<td>BAP1</td>
</tr>
<tr>
<td>BARD1</td>
</tr>
<tr>
<td>BLM</td>
</tr>
<tr>
<td>BMPR1A</td>
</tr>
<tr>
<td>BRCA1</td>
</tr>
<tr>
<td>BRCA2</td>
</tr>
<tr>
<td>BRIP1</td>
</tr>
<tr>
<td>CDC73</td>
</tr>
<tr>
<td>CDH1</td>
</tr>
<tr>
<td>CDK4</td>
</tr>
<tr>
<td>CDKN1B</td>
</tr>
<tr>
<td>CDK2N2A</td>
</tr>
<tr>
<td>CHEK2</td>
</tr>
<tr>
<td>CTNNB1</td>
</tr>
<tr>
<td>DICER1</td>
</tr>
<tr>
<td>EGFR</td>
</tr>
<tr>
<td>EGLN1</td>
</tr>
<tr>
<td>EPCAM</td>
</tr>
<tr>
<td>FANCC</td>
</tr>
<tr>
<td>FH</td>
</tr>
<tr>
<td>FLCN</td>
</tr>
<tr>
<td>GALNT12</td>
</tr>
<tr>
<td>GREM1</td>
</tr>
<tr>
<td>HOXB13</td>
</tr>
<tr>
<td>KIF1B</td>
</tr>
<tr>
<td>KIT</td>
</tr>
<tr>
<td>LZTR1</td>
</tr>
<tr>
<td>MAX</td>
</tr>
<tr>
<td>MEN1</td>
</tr>
<tr>
<td>MET</td>
</tr>
<tr>
<td>MITF</td>
</tr>
<tr>
<td>MLH1</td>
</tr>
<tr>
<td>MSH2</td>
</tr>
<tr>
<td>MSH3</td>
</tr>
<tr>
<td>MSH6</td>
</tr>
<tr>
<td>MUTYH</td>
</tr>
<tr>
<td>NBN</td>
</tr>
<tr>
<td>NF1</td>
</tr>
<tr>
<td>NF2</td>
</tr>
<tr>
<td>NTHL1</td>
</tr>
<tr>
<td>PALB2</td>
</tr>
<tr>
<td>PDGFRA</td>
</tr>
<tr>
<td>PHOX2B</td>
</tr>
<tr>
<td>PMS2</td>
</tr>
<tr>
<td>POLD1</td>
</tr>
<tr>
<td>POLE</td>
</tr>
<tr>
<td>POT1</td>
</tr>
<tr>
<td>PRKAR1A</td>
</tr>
<tr>
<td>PTCH1</td>
</tr>
<tr>
<td>PTEN</td>
</tr>
<tr>
<td>RAD51C</td>
</tr>
<tr>
<td>RAD51D</td>
</tr>
<tr>
<td>RB1</td>
</tr>
<tr>
<td>RECQL</td>
</tr>
<tr>
<td>RET</td>
</tr>
<tr>
<td>SDHA</td>
</tr>
<tr>
<td>SDHAF2</td>
</tr>
<tr>
<td>SDHB</td>
</tr>
<tr>
<td>SDHC</td>
</tr>
<tr>
<td>SDHD</td>
</tr>
<tr>
<td>SMAD4</td>
</tr>
<tr>
<td>SMARCA4</td>
</tr>
<tr>
<td>SMARCB1</td>
</tr>
<tr>
<td>SMARCE1</td>
</tr>
<tr>
<td>STK11</td>
</tr>
<tr>
<td>SUFU</td>
</tr>
<tr>
<td>TMEM127</td>
</tr>
<tr>
<td>TP53</td>
</tr>
<tr>
<td>TSC1</td>
</tr>
<tr>
<td>TSC2</td>
</tr>
<tr>
<td>VHL</td>
</tr>
<tr>
<td>XRCC2</td>
</tr>
</tbody>
</table>

**xG (CancerNext®) — 36 Genes:**

<table>
<thead>
<tr>
<th>Gene</th>
</tr>
</thead>
<tbody>
<tr>
<td>APC</td>
</tr>
<tr>
<td>ATM</td>
</tr>
<tr>
<td>AXIN2</td>
</tr>
<tr>
<td>BARD1</td>
</tr>
<tr>
<td>BMPR1A</td>
</tr>
<tr>
<td>BRCA1</td>
</tr>
<tr>
<td>BRCA2</td>
</tr>
<tr>
<td>BRIP1</td>
</tr>
<tr>
<td>CDK4</td>
</tr>
<tr>
<td>CDK2N2A</td>
</tr>
<tr>
<td>CHEK2</td>
</tr>
<tr>
<td>DICER1</td>
</tr>
<tr>
<td>EPCAM</td>
</tr>
<tr>
<td>GREM1</td>
</tr>
<tr>
<td>HOXB13</td>
</tr>
<tr>
<td>MLH1</td>
</tr>
<tr>
<td>MSH2</td>
</tr>
<tr>
<td>MSH3</td>
</tr>
<tr>
<td>MSH6</td>
</tr>
<tr>
<td>MUTYH</td>
</tr>
<tr>
<td>NBN</td>
</tr>
<tr>
<td>NF1</td>
</tr>
<tr>
<td>NTHL1</td>
</tr>
<tr>
<td>PALB2</td>
</tr>
<tr>
<td>POLD1</td>
</tr>
<tr>
<td>POLE</td>
</tr>
<tr>
<td>PTEN</td>
</tr>
<tr>
<td>RAD51C</td>
</tr>
<tr>
<td>RAD51D</td>
</tr>
<tr>
<td>RECQL</td>
</tr>
</tbody>
</table>

**xG (CancerNext®) and xG+ (CancerNext-Expanded®) powered by Ambry Genetics® is available to select providers.**

---

**We help provide access to our tests for patients in financial need.**

All Tempus tests, including xG/xG+, are eligible under the program. Patients can complete the application online at [access.tempus.com](http://access.tempus.com) or call **800.739.4137** to speak to a member of our team.

If you have any questions on our comprehensive portfolio of available tests, please contact your Tempus Representative or email [support@tempus.com](mailto:support@tempus.com)

---

2023-11